nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives

•Current definition of nmCRPC: confirmed rising PSA levels during ADT with no evidence of metastases on conventional imaging.•nmCRPC: men with a PSA doubling time ≤10 months are at higher risk of developing metastases.•ADT only was the previous standard of care for nmCRPC.•Apalutamide, enzalutamide and darolutamide plus ADT significantly prolonged MFS and OS.•The observed low incidence of drug related adverse events with ARTAs in nmCRPC, maintain patients’ HRQoL.